Activ Surgical New Appointments

Richard Stamm as Vice President, General Counsel and Mark Johnson as Vice President, Global Sales

Richard Stamm has been appointed vice president, general counsel, and Mark Johnson as vice president, global sales. In his role as general counsel, Stamm will oversee all aspects of Activ Surgical’s legal and corporate governance matters, while Johnson will spearhead the company’s sales organization.

These key executive appointments are being made between two significant company milestones–a $45 million Series B fundraise, announced in September 2021, and commercialization of its ActivInsights™ software suite, which is targeted for early 2022.

Richard Stamm brings 30 years of corporate and securities law experience to Activ Surgical. He started his career with leading law firm Dechert, LLP., before moving in-house at Ocean Spray Cranberries, Inc. where, as general counsel, he provided strategic guidance on the full range of legal issues faced by a global branded company. Following Ocean Spray, Stamm joined Agrify Corporation as its general counsel, helping to navigate the company through the legal complexities in preparing for its initial public offering (IPO). Most recently, he maintained his own legal and consulting firm, leveraging his practical business law and corporate governance expertise to advise a variety of businesses and their leaders. Stamm has a degree in business economics from Brown University and received his law degree from the University of Connecticut School of Law.

“I am excited to join Activ Surgical at a critical inflection point in the company’s history,” said Stamm. “With the impending commercial launch of its ActivInsight software suite, there is an abundance of interrelated commercial, business and regulatory activities to manage. I look forward to working with the Activ Surgical leadership team and the entire organization to guide them through these complexities.”

Johnson is a proven sales leader and executive with 20+ years of experience, and comes to Activ Surgical from Hologic, Inc., where he led the U.S. Commercial Skeletal business, as well as Western U.S. Breast and Skeletal Health team with collective sales and service revenue responsibility of $400M+. Across his leadership roles, he has excelled in his responsibilities of driving sales transformation, increasing revenue and profitability growth, attracting and selecting top talent, employee development, sales targeting and optimization, cross-functional leadership, culture development, and key account management. Previous to his time at Hologic, Johnson held leadership positions at Stryker, Smith & Nephew, and Elekta. He has a degree in biology from The University of Georgia.

“With preventable surgical errors costing our global healthcare system approximately $36 billion dollars, Activ Surgical and its innovative technology platform have a massive opportunity to usher in a new era of patient care and safety in the operating room,” said Johnson. “I plan to embrace the growth opportunities ahead as the company moves toward commercialization and am confident we will fulfill our mission to democratize surgical care around the globe.”

“Activ Surgical is growing rapidly after our Series B fundraise in September of this year, and Rich and Mark will both play critical roles in continuing this upward trajectory and ensuring success for the commercial launch of our first product–the ActivInsights software suite–in 2022,” said Todd, Usen, chief executive officer, Activ Surgical. “Both executives bring an outstanding track record in their respective fields, and I am thrilled to have them join our leadership team.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”